Edition:
India

Alnylam Pharmaceuticals Inc (ALNY.OQ)

ALNY.OQ on NASDAQ Stock Exchange Global Select Market

131.00USD
22 Jan 2018
Change (% chg)

$6.17 (+4.94%)
Prev Close
$124.83
Open
$126.07
Day's High
$132.32
Day's Low
$126.07
Volume
628,167
Avg. Vol
491,267
52-wk High
$147.63
52-wk Low
$35.98

Chart for

About

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs... (more)

Overall

Beta: 2.97
Market Cap(Mil.): $11,251.10
Shares Outstanding(Mil.): 91.73
Dividend: --
Yield (%): --

Financials

BRIEF-Sanofi And Alnylam Pharmaceuticals Enter Into Partnership

* AND ALNYLAM, ANNOUNCED ON SUNDAY STRATEGIC RESTRUCTURING OF RNAI THERAPEUTICS RARE DISEASE ALLIANCE

08 Jan 2018

Sanofi to market new hemophilia drug in deal with Alnylam

PARIS French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

08 Jan 2018

Sanofi to market new hemophilia drug in deal with Alnylam

PARIS, Jan 8 French pharmaceutical group Sanofi said it has obtained the right to develop and sell a new hemophilia drug in a restructuring of its partnership with U.S. Alnylam Pharmaceuticals.

08 Jan 2018

BRIEF-Alnylam And Sanofi Submit Marketing Authorisation Application (MAA) To The European Medicines Agency (EMA)

* ALNYLAM AND SANOFI SUBMIT MARKETING AUTHORISATION APPLICATION (MAA) TO THE EUROPEAN MEDICINES AGENCY (EMA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS Source text for Eikon: Further company coverage:

18 Dec 2017

BRIEF-‍Sanofi, Alnylam submit marketing authorization application to EMA for Patisiran

* Sanofi and Alnylam submit Marketing Authorization Application to the European Medicines Agency for patisiran for the treatment of hereditary ATTR amyloidosis

18 Dec 2017

BRIEF-FDA Lifts Clinical Hold On Fitusiran

* ALNYLAM PHARMACEUTICALS INC - CLINICAL TRIAL DOSING TO RESUME AROUND YEAR-END 2017

15 Dec 2017

FDA allows Alnylam to restart hemophilia treatment trials

The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

15 Dec 2017

UPDATE 1-FDA allows Alnylam to restart hemophilia treatment trials

Dec 15 The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical trials on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

15 Dec 2017

FDA allows Alnylam to restart hemophilia treatment trials

Dec 15 The U.S. Food and Drug Administration has allowed Alnylam Pharmaceuticals Inc to restart clinical tests on a drug to treat patients with a rare bleeding disorder, the company said on Friday.

15 Dec 2017

BRIEF-Alnylam Completes NDA Submission To U.S. FDA For Patisiran For Treatment Of HATTR Amyloidosis

* ALNYLAM COMPLETES SUBMISSION OF NEW DRUG APPLICATION TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR PATISIRAN FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS Source text for Eikon: Further company coverage:

12 Dec 2017

Earnings vs. Estimates